Seven percent hypertonic saline—0.1% hyaluronic acid in infants with mild‐to‐moderate bronchiolitis. Issue 9 (4th November 2013)

• Record Type: Journal Article
• Authors: Nenna, Raffaella; Papoff, Paola; Moretti, Corrado; De Angelis, Daniela; Battaglia, Massimo; Papasso, Stefano; Bernabucci, Mariangela; Cangiano, Giulia; Petrarca, Laura; Salvadei, Serena; Nicolai, Ambra; Ferrara, Marianna; Bonci, Enea; Midulla, Fabio
• Is Part Of: Pediatric pulmonology. Volume 49:Issue 9(2014:Sep.)
• Page Start: 919
• Page End: 925
• Publication Date: 2013-11-04
• Subjects: Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.22935
• Languages: English
• ISSNs: 8755-6863

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Summary</title> <sec id="ppul22935-sec-0001" sec-type="section"> <title>Objectives</title> <p>Our study was aimed to evaluate the efficacy of 7% hypertonic saline and 0.1% hyaluronic acid (7% HS–HA) given by inhalation, in infants hospitalized for mild‐to‐moderate bronchiolitis.</p> </sec> <sec id="ppul22935-sec-0002" sec-type="section"> <title>Methods</title> <p>In a double‐blind controlled study, 39 infants (23 boys) <7 months of age (median age 2 months) were enrolled and randomly assigned to receive either nebulized 7% HS–HA (7%NaCl + 0.1%HA) (n:21) or 0.9 normal saline (NS) (n:18) at a dose of 2.5 ml twice a day for 3 days. All infants were assigned a clinical severity score at admission and four times daily during hospitalization. Main outcome measures were number of days hospitalization, safety and daily reduction in the severity score.</p> </sec> <sec id="ppul22935-sec-0003" sec-type="section"> <title>Results</title> <p>No difference was found between the two groups for clinical severity score at admission. One child in the study group and two in the NS group interrupted the study protocol; 19% of infants in the study group and 11% in the NS group had mild cough after the aerosol. The length of stay in the control group and treatment groups were 4.8 ± 1.5 versus 4.1 ± 1.9 days, respectively (<italic>P</italic> = 0.09). There was a trend for shortening the hospitalization days in the treatment group by 14.6%. The use of NS in the control group was identified as an independent risk factor for length of hospital stay using the multivariate logistic regression model (<italic>P</italic> = 0.04). No difference was observed between the two groups for the clinical score reduction during the first 3 days hospitalization.</p> </sec> <sec id="ppul22935-sec-0004" sec-type="section"> <title>Conclusions</title> <p>7% HS–HA is a safe and effective therapy in treating infants hospitalized for mild‐to‐moderate bronchiolitis. <bold>Pediatr Pulmonol. 2014; 49:919–925.</bold> © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>